Pediatrix Medical falls -10.9%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 22 2025
0mins
- Stock Performance: Pediatrix Medical has experienced a decline of 10.9%, resulting in a decrease of $3.46, bringing the stock price down to $28.30.
- Data Context: The information is based on data available up to October 2023.
Analyst Views on PDX
Wall Street analysts forecast PDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PDX is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 19.790
Low
Averages
High
Current: 19.790
Low
Averages
High
No data
About PDX
PIMCO Dynamic Income Strategy Fund is a non-diversified, limited term, closed-end management investment company. The Fund seeks to achieve its investment objectives by utilizing a dynamic asset allocation strategy among multiple sectors in the global public and private credit markets, including corporate debt, mortgage-related and other asset-backed instruments, government and sovereign debt, taxable municipal bonds and other fixed-, variable- and floating-rate income-producing securities of United States (U.S.) and foreign issuers, including emerging market issuers and real estate-related investments. The Fund may invest without limitation in investment grade debt securities and below investment grade debt securities (high yield securities or junk bonds), including securities of stressed, distressed or defaulted issuers. The Fund normally invests at least 25% of its total assets in the energy industry. The Fund's investment manager is Pacific Investment Management Company LLC.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
